CERE 120

Drug Profile

CERE 120

Alternative Names: AAV-NRTN; AAV-NTN; AAV2-neurturin; AAV2-NTN; CERE-120; Neurturin gene therapy

Latest Information Update: 11 Jan 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Ceregene
  • Developer Sangamo BioSciences
  • Class Antiparkinsonians; Gene therapies
  • Mechanism of Action Nerve tissue protein modulators; Neurturin agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Eye-Disorders; Huntington's disease; Parkinson's disease

Most Recent Events

  • 06 Jan 2017 Sangamo Biosciences is now called Sangamo Therapeutics
  • 01 Mar 2015 Discontinued - Phase-II for Parkinson's disease in United Kingdom (Intrastriatal)
  • 01 Mar 2015 Discontinued - Phase-II for Parkinson's disease in USA (Intrastriatal)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top